- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00599664
Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones
28. april 2010 opdateret af: Omeros Corporation
Double-Blind, Placebo-Controlled, Two-Center, Pharmacokinetic Study Evaluating the Systemic Absorption and Safety of OMS201 in Subjects Undergoing Ureteroscopic Treatment of Unilateral Ureteral- or Renal Collecting System-Located Stones
Evaluate the safety and systemic absorption of OMS201 following exposure during ureteroscopy.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OMS201 is being developed to facilitate endoscopy of the ureters and to reduce postoperative discomfort, such as pain, frequency, urgency and/or difficult urination following endoscopic surgery to remove a urinary tract stone.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
11
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
California
-
Orange, California, Forenede Stater, 92868
- UC Irvine Medical Center
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- University of Texas Southwestern
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Subject is undergoing unilateral ureteroscopic removal of renal collecting system or ureteral stones located in the ureter with a maximum stone diameter of 12 mm, for which general anesthesia will be used.
- Subject's physical examination is within normal limits or examination is clinically non-significant for purposes of the study as determined by the Investigator, and subject is in good general health.
- Subject's laboratory evaluations are within normal limits or evaluations are clinically non-significant as determined by the Investigator.
- Female subject of childbearing potential who is using an effective method of birth control within at least 14 days prior to surgery and has a negative pregnancy test.
- Subject is at minimal risk from anesthesia and is classified according to the American Society of Anesthesiologists Physical Status Classification as either PS-1 or PS-2.
- Subject's body mass index is between 19 and 35, inclusive, based on the Body Mass Index Table.
Exclusion Criteria:
- Subject taking a prohibited medication.
- Subject who has had a renal transplant, has a single kidney or has evidence of a compromised renal function as measured by abnormal serum creatinine, as judged by the Investigator, or who has evidence of urinary tract infection, or has prior history of open or laparoscopic surgery, or any history of an ureteral stricture.
- Subject who has congenital anomalies that would engender an increased procedural safety risk such as ureteropelvic junction obstruction resulting in severely dilated renal pelvis, duplicated urinary collecting system, horseshoe kidney or vascular anomalies such as renal arteriovenous fistulas or papillary necrosis.
- Subject has bilateral renal or ureteral stones requiring concurrent ureteroscopic removal.
- Subject with clinically significant hypotension at Screening.
- Subject who has a present condition or history of any clinically significant uncontrolled gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, connective tissue, respiratory or other medical disorder as determined by the Investigator.
- Subject on chronic diuretic use.
- Subject who has taken or used an investigational drug or device within 30 days prior to the day of surgery.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: 2
Køretøj
|
Vehicle irrigation solution during surgery
|
|
Eksperimentel: 1
Medicin
|
OMS201 irrigation solution during surgery
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Pharmacokinetic
Tidsramme: Day of Surgery
|
Day of Surgery
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Safety
Tidsramme: Day 7
|
Day 7
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: Scott Houston, Omeros Corporation
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2007
Studieafslutning (Faktiske)
1. september 2008
Datoer for studieregistrering
Først indsendt
26. december 2007
Først indsendt, der opfyldte QC-kriterier
10. januar 2008
Først opslået (Skøn)
24. januar 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
30. april 2010
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
28. april 2010
Sidst verificeret
1. april 2010
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- C07-001
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Urinvejsregning
-
TC Erciyes UniversityAfsluttet
-
University of Sao PauloAfsluttetNyre Calculi | Urolithiasis | Urinary LithiasisBrasilien
-
Neuspera Medical, Inc.Aktiv, ikke rekrutterendeUrinary Urgency InkontinensForenede Stater, Holland, Belgien
-
Oregon Health and Science UniversityAfsluttetUrinary Urgency InkontinensForenede Stater
-
Albany Medical CollegeIkke rekrutterer endnu
-
Neuspera Medical, Inc.RekrutteringUrinary Urgency InkontinensForenede Stater
-
Yale UniversityAfsluttetNyresygdomme | Smerter, postoperativ | Nyresten | Urinary LithiasisForenede Stater
-
NovaBay Pharmaceuticals, Inc.UkendtUrinary Catheter Blokering og EncrustationForenede Stater
-
HydrumedicalClinical Academic Center (2CA-Braga); Blueclinical, Ltd.Rekruttering
-
University Hospital, Strasbourg, FranceRekruttering